Skip to content
Insider tapeFilings through Fri, Nov 20
My stocks

Reshma Kewalramani

At a glance: Reshma Kewalramani is CEO, President at Vertex Pharmaceuticals (VRTX). Their latest SEC Form 4, filed Nov 10, 2026, reported a sale of $6.3M. On file: 0 purchase lines ($0) and 14 sale lines ($26.0M).

Disclosed holdings: about $44.5M of VRTX stock: 86,471 shares reported on their latest Form 4 (filed Nov 10, 2026), valued at the Nov 20, 2026 close of $515.02. This counts only VRTX shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

CEO, President at Vertex Pharmaceuticals Inc / Ma (VRTX)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $26.0M

Reshma Kewalramani's InsiderPrint

16 trades from SEC Form 4 filings, 2021 to 2026, drawn as one fingerprint.

InsiderPrint of Reshma Kewalramani: 16 trades, 2021 to 20262021: 1 buy, 0 sales2022: 0 buys, 0 sales2023: 0 buys, 0 sales2024: 0 buys, 0 sales2025: 1 buy, 0 sales2026: 0 buys, 14 sales

Reading this print: Mostly sells, trading about 3 times a year, typically $1.2M a trade; most sales are on a pre-planned 10b5-1 schedule; trades in the same month most years.

  • Bump outward: a purchase (2)
  • Dent inward: a sale (14)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. Stephane BancelCEO · MRNA · 94% match
  2. Trevor R. BurgessCEO · NP · 93% match
  3. William C. CobbCEO · FTDR · 90% match
  4. Clarence L. GrangerDirector · UCTT · 89% match
  5. Eric M. SprinkCEO · CCB · 89% match

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
Nov 10SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 11,86686,471 held (−12%) $531.53 $6.3M -3.1%
Mar 3SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 400137,878 held (−0%) $479.75 $192K +7.4%
Mar 3SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 120137,758 held (−0%) $481.50 $58K +7.0%
Mar 3SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 240137,518 held (−0%) $482.84 $116K +6.7%
Mar 3SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 2,510135,008 held (−2%) $487.13 $1.2M +5.7%
Mar 3SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 3,278131,730 held (−2%) $488.27 $1.6M +5.5%
Mar 3SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 460131,270 held (−0%) $489.32 $225K +5.3%
Mar 3SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 2,725128,545 held (−2%) $490.54 $1.3M +5.0%
Mar 3SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 949127,596 held (−1%) $491.30 $466K +4.8%
Mar 3SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 2,520125,076 held (−2%) $493.29 $1.2M +4.4%
Mar 3SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 3,498121,578 held (−3%) $494.33 $1.7M +4.2%
Mar 3SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 15,580105,998 held (−13%) $495.38 $7.7M +4.0%
Mar 3SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 5,995100,003 held (−6%) $496.16 $3.0M +3.8%
Mar 3SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 1,72598,278 held (−2%) $496.95 $857K +3.6%
  • Sell

    CEO, President Reshma Kewalramani sold $6.3M of VRTX at $531.53 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CEO, President Reshma Kewalramani sold $192K of VRTX at $479.75 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CEO, President Reshma Kewalramani sold $58K of VRTX at $481.50 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CEO, President Reshma Kewalramani sold $116K of VRTX at $482.84 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CEO, President Reshma Kewalramani sold $1.2M of VRTX at $487.13 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CEO, President Reshma Kewalramani sold $1.6M of VRTX at $488.27 — pre-scheduled 10b5-1 plan sale.

Follow Reshma Kewalramani

Get one email when Reshma Kewalramani files a new purchase or sale. Free.

At most one email a day about Reshma Kewalramani, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.